Founder’s Vision
ANKTIVA®
BCG
Clinical Trials
Find a Trial
Become a Trial
Investigator
License our Cells
Science
Platforms
Pipeline
Expanded Access
Research
Approach
Patients
Trial Investigators
Researchers
Condition
Bladder Cancer
Glioblastoma
HIV
Lynch / Colon Cancer
Non-Hodgkin Lymphoma
Ovarian Cancer
Human Papillomavirus
Non-Small Cell Lung Cancer
Company
About Us
Investors
News and Events
Contact
Careers
Select Page
Acceptance Requirements
Adult patients diagnosed with histologically-confirmed glioblastoma that has progressed after initial therapy or therapies
Must have previous first line treatment with at least radiotherapy and temozolomide.
Search for:
Recent Posts
ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites in the Process of Launching
ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024
ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer
FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage
AUA 2025